Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.78 |
| ▸ | CNR2 | P34972 | 2/20 | 0.78 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | CKS1B | P61024 | 1/20 | 0.34 |
| ▸ | SKP1 | P63208 | 1/20 | 0.34 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14545613 | 0.87 | CNR1 (0.72) | CNR1CNR2CKS1BSKP1SKP2 | |
| SCHEMBL14545302 | 0.86 | CNR1 (0.80) | CNR1CNR2CKS1BSKP1SKP2 | |
| SCHEMBL14545384 | 0.84 | CNR1 (0.77) | CNR1CNR2CKS1BSKP1SKP2 | |
| SCHEMBL5515537 | 0.82 | CNR1 (0.73) | CNR1CNR2CKS1BSKP1SKP2 | |
| SCHEMBL14544965 | 0.80 | CNR1 (0.67) | CNR1CNR2 | |
| SCHEMBL14545443 | 0.77 | CNR1 (0.58) | CNR1CNR2PDE10A | |
| SCHEMBL14544955 | 0.76 | CNR1 (0.65) | CNR1CNR2GSK3B | |
| SCHEMBL14545501 | 0.75 | CNR1 (0.77) | CNR1CNR2CKS1BSKP1SKP2 | |
| SCHEMBL14545441 | 0.75 | CNR1 (0.62) | CNR1CNR2 | |
| SCHEMBL14545456 | 0.75 | CNR1 (0.62) | CNR1CNR2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | CNR1 1/4885CNR2 2/4885PIM1 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.